Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Φάρμακα Α - Ζ  Συγχορήγηση  Μητρότητα

NALPAIN Solution for injection (2011)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

NALPAIN 10 mg/ml solution for injection.

Qualitative and quantitative composition

1 ml solution for injection contains 10 mg nalbuphine hydrochloride. 1 ampoule of 2 ml contains 20 mg nalbuphine hydrochloride. Excipient: 1.6 mg sodium in a 2 ml ampoule. For a full list of excipients, ...

Pharmaceutical form

Solution for injection. The solution is clear and colourless. pH = 3.0-4.2, osmolarity = 0.3 Osmol/kg

Therapeutic indications

NALPAIN 10 mg/ml solution for injection is indicated for the short-term relief of moderate to severe pain. It can also be used for pre- and postoperative analgesia.

Posology and method of administration

Adults The usual recommended dose for adults is 10-20 mg for patients with 70 kg body weight, which is equivalent to 0.1–0.3 mg/kg body weight. This dose may be administered intravenously, intramuscularly ...

Contraindications

hypersensitivity to the active substance or to any of the excipients severe renal impairment hepatic impairment concomitant treatment with μ-agonistic opioids e.g. morphine and fentanyl (see section 4.5) ...

Special warnings and precautions for use

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially sodium-free. Opioid dependence NALPAIN 10 mg/ml solution for injection may not be used as a substitute for heroin, ...

Interaction with other medicinal products and other forms of interaction

Contra-indicated combinations + Pure morphine agonists (such as morphine, pethidine, dextromoramide, dihydrocodeine, dextropropoxyphene, methadone, levacethylmethadol): Pure μ-agonists reduce analgesic ...

Pregnancy and lactation

Usage during pregnancy There are inadequate data regarding the use of nalbuphine hydrochloride in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk ...

Effects on ability to drive and use machines

NALPAIN 10 mg/ml solution for injection reduces the ability to respond and has therefore a major influence on the ability to drive and use machines. These activities have to be avoided until the effects ...

Undesirable effects

The following undesirable effects are ranked according to system organ class and to their frequency: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1.000 to <1/100), Rare (≥1/10.000 to <1/1.000), ...

Overdose

Administration of high doses of nalbuphine hydrochloride (intramuscular or intravenous) produces several symptoms of overdose like respiratory depression, sedation, sleepiness, unconsciousness and light ...

Pharmacodynamic properties

Pharmacotherapeutic group: Opioids, Morphinane derivatives ATC code: N02AF02 Nalbuphine hydrochloride is an opioid with kappa-agonistic and mu-antagonistic properties. Beside the essential agonistic (analgesic) ...

Pharmacokinetic properties

In adults, the effect takes place 2 to 3 minutes after intravenous administration and less than 15 minutes after intramuscular or subcutaneous injection. The duration of action ranges from 3 to 6 hours.The ...

Preclinical safety data

Reproductive toxicity studies with parenterally administered nalbuphine were performed in rats and rabbits. In a pre- and postnatal study in rats, an increase in pre- and postnatal mortality and a decrease ...

List of excipients

Citric acid, anhydrous Sodium citrate Sodium chloride Hydrochloric acid (for pH adjustment) Water for injection

Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Shelf life

Shelf life: 3 years. The product has to be used immediately after opening.

Special precautions for storage

Do not store above 25°C. Keep the ampoules in the outer carton in order to protect from light.

Nature and contents of container

Colourless glass, Type I. Ampoules of 2 ml, in packages of 10 ampoules.

Special precautions for disposal

For single use only. Only clear solutions practically free from particles should be used. The solution must be visually inspected prior to use. Any unused solution should be disposed of in accordance with ...

Marketing authorization holder

Orpha-Devel Handels und Vertriebs GmbH, Wintergasse 85/1B, A-3002, Purkersdorf, Austria

Marketing authorization number(s)

PL 30414/0003

Date of first authorization / renewal of the authorization

21/02/2008 / 20/01/2011

Date of revision of the text

20/01/2011

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: